Statin adjunctive therapy shortens the duration of TB treatment in mice
Journal of Antimicrobial Chemotherapy2016Vol. 71(6), pp. 1570–1577
Citations Over TimeTop 10% of 2016 papers
Noton K. Dutta, Natalie Bruiners, Michael L. Pinn, Matthew Zimmerman, Brendan Prideaux, Véronique Dartois, Maria Laura Gennaro, Petros C. Karakousis
Abstract
Statins are attractive candidates for host-directed, adjunctive TB therapy. Further preclinical studies are needed to define the optimal statin and dosing.
Related Papers
- → The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions(2018)113 cited
- → A data-driven methodology towards evaluating the potential of drug repurposing hypotheses(2021)29 cited
- → Treatment Repurposing using Literature-related Discovery(2019)4 cited
- → Drug Repurposing and Multi-Target Therapies(2018)2 cited
- → Faculty Opinions recommendation of Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.(2021)